Ovarian Cancer Clinical Trial
Nirogacestat in Ovarian Granulosa Cell Tumors
This phase 2 clinical trial will study the effectiveness of nirogacestat in ovarian granulosa cell tumors (OvGCTs). Nirogacestat is a gamma secretase inhibitor (GSI) which is hypothesized to decrease the growth and activity of ovarian granulosa tumors.
Ovarian granulosa cell tumors (OvGCTs) represent 5-7% of all ovarian cancers (~1.5 to 2k newly diagnosed patients/year in the United States) and are the most common subtype of ovarian sex cord tumors (70%). Treatment of granulosa cell tumors with nirogacestat is expected to inhibit Notch-induced granulosa cell proliferation.
This is a multi-center, single-arm, Phase 2 open label treatment study to determine the efficacy, safety, tolerability, and pharmacokinetics of nirogacestat in adult participants with relapsed/refractory OvGCT. The participants will continue treatment until disease progression as determined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 (unless the participants meet criteria for continued treatment) or unacceptable toxicity.
Key Inclusion Criteria:
Has histologically confirmed recurrent adult-type granulosa cell tumor of the ovary prior to first dose of study treatment
Have documented radiological evidence of relapse after at least one systemic therapy that is not amenable to surgery, or radiation and have measurable disease by RECIST v1.1 criteria
Have adequate bone marrow, renal and hepatic function as defined by screening visit laboratory values
Key Exclusion Criteria:
Has signs of bowel obstruction requiring parenteral nutrition, malabsorption syndrome or preexisting gastrointestinal conditions that may impair absorption of nirogacestat
Has had a major cardiac or thrombo-embolic event within 6 months of signing informed consent
Has abnormal QT interval at Screening, or has congenital or acquired long QT syndrome or a history of additional risk factors for Torsades de Pointes
Has current or chronic history of liver disease or known hepatic or biliary abnormalities
Has received bevacizumab treatment or other monoclonal antibody therapy with targeted anti-angiogenic activity for OvGCT within 28 days (or 5 half-lives, whichever is shorter) prior to the first dose of study treatment;
Has received treatment for OvGCT including but not limited to the following within 28 days (or 5 half-lives, whichever is longer) prior to the first dose of study treatment: hormonal therapy, chemotherapy, immunotherapy, targeted therapy or any investigational treatment
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 21 Locations for this study
Los Angeles California, 90033, United States
Los Angeles California, 90095, United States
Orlando Florida, 32804, United States
Orlando Florida, 32806, United States
Tampa Florida, 33612, United States
Covington Louisiana, 70433, United States
Baltimore Maryland, 21204, United States
Boston Massachusetts, 02215, United States
Saint Louis Missouri, 63141, United States
Albuquerque New Mexico, 87102, United States
New York New York, 10032, United States
New York New York, 10065, United States
Kettering Ohio, 45429, United States
Oklahoma City Oklahoma, 73104, United States
Seattle Washington, 98109, United States
Milwaukee Wisconsin, 53226, United States
Edmonton Alberta, T6G 1, Canada
BiaÅ‚ystok , 15-02, Poland
KrakÃ³w , 30-34, Poland
PoznaÅ„ , 60-56, Poland
Warsaw , 02-78, Poland
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.